We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-16.51%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.2B
AUM Growth
+$184M
(+6.1%)
Cap. Flow
+$679M
Cap. Flow
% of AUM
21.24%
Top 10 Holdings %
Top 10 Hldgs %
52.91%
Holding
52
New
11
Increased
20
Reduced
7
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$126M |
| 2 |
Danaher
DHR
|
+$126M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$124M |
| 4 |
Intuitive Surgical
ISRG
|
+$105M |
| 5 |
IQVIA
IQV
|
+$93.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$218M |
| 2 |
Merck
MRK
|
+$132M |
| 3 |
HCA Healthcare
HCA
|
+$118M |
| 4 |
AGN
Allergan plc
AGN
|
+$117M |
| 5 |
Labcorp
LH
|
+$106M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Merck
MRK
$322B
| $47.7M | 1.49% |
654,036
-1,870,470
| -74% | -$132M |
|
|
DVAX
27
DELISTED
Dynavax Technologies
DVAX
| $42.2M | 1.32% |
4,613,280
+1,491,811
| +48% | +$16.5M |
|
|
AMRN
28
Amarin Corp
AMRN
$299M
| $41.5M | 1.3% |
+152,304
| New | +$55.5M |
|
29
Vertex Pharmaceuticals
VRTX
$121B
| $32M | 1% |
192,810
-9,370
| -5% | -$1.62M |
|
30
Amneal Pharmaceuticals
AMRX
$5.85B
| $28.7M | 0.9% |
2,118,377
+1,082,267
| +104% | +$19.5M |
|
|
VRAY
31
DELISTED
ViewRay, Inc.
VRAY
| $27.3M | 0.85% |
4,503,630
+1,981,250
| +79% | +$14.8M |
|
|
32
Zimmer Biomet
ZBH
$18.2B
| $25.3M | 0.79% |
251,522
-1,937,228
| -89% | -$218M |
|
33
Biogen
BIIB
$30B
| $20.1M | 0.63% |
66,780
+55,170
| +475% | +$17.6M |
|
34
Humana
HUM
$43.7B
| $18.6M | 0.58% |
+64,830
| New | +$20.6M |
|
|
CVRS
35
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $16.8M | 0.52% |
19,981,655
| – | – |
|
36
Bristol-Myers Squibb
BMY
$133B
| $15.3M | 0.48% |
+294,490
| New | +$15.8M |
|
|
CLVS
37
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.8M | 0.34% |
+600,000
| New | +$12.3M |
|
|
PTE
38
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $9.73M | 0.3% |
28,852
| – | – |
|
|
NVRO
39
DELISTED
NEVRO CORP.
NVRO
| $6.04M | 0.19% |
+155,410
| New | +$6.91M |
|
|
ZSAN
40
DELISTED
Zosano Pharma Corporation
ZSAN
| $1.21M | 0.04% |
16,309
+440
| +3% | +$55.7K |
|
41
Bio-Rad Laboratories Class A
BIO
$8.71B
| – | – |
-16,240
| Closed | -$5.08M |
|
42
Quest Diagnostics
DGX
$25.7B
| – | – |
-735,930
| Closed | -$79.4M |
|
43
Elevance Health
ELV
$81.5B
| – | – |
-304,270
| Closed | -$83.4M |
|
44
Edwards Lifesciences
EW
$49.6B
| – | – |
-1,361,145
| Closed | -$79M |
|
45
Gilead Sciences
GILD
$162B
| – | – |
-132,870
| Closed | -$10.3M |
|
|
46
HCA Healthcare
HCA
$87.2B
| – | – |
-850,000
| Closed | -$118M |
|
47
ICU Medical
ICUI
$4.21B
| – | – |
-10,380
| Closed | -$2.94M |
|
|
48
Labcorp
LH
$25B
| – | – |
-708,011
| Closed | -$106M |
|
|
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-1,032,127
| Closed | -$63.5M |
|
|
CERN
50
DELISTED
Cerner Corp
CERN
| – | – |
-729,050
| Closed | -$47M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2018 Portfolio in Review
As of Q4 2018, HealthCor Management held 52 positions worth $3.2B, up 6.1% from $3.02B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
HealthCor Management deployed $679M of net new capital in Q4 2018, opening 11 new positions and adding to 20 existing holdings. Its largest new stake was Wellcare Health Plans, Inc.: 462,370 shares worth $109M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 88% a quarter earlier.
On the sell side, the largest reduction was Zimmer Biomet, an estimated $218M trimmed.
- HealthCor Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 462,370 shares worth $109M.
- HealthCor Management added most to DexCom in Q4 2018, an estimated $126M increase.
- HealthCor Management's biggest Q4 2018 reduction was Zimmer Biomet, cutting an estimated $218M.
- HealthCor Management fully exited HCA Healthcare in Q4 2018, selling an estimated $118M.
- HealthCor Management's ten largest holdings make up 53% of its $3.2B portfolio in Q4 2018.
- HealthCor Management opened 11 new positions and closed 12 in Q4 2018.
- HealthCor Management's portfolio value rose 6.1% quarter-over-quarter to $3.2B.
Based on HealthCor Management's 13F filing for Q4 2018, filed 14 Feb 2019.